Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.

Gisela Kobelt, Johan Berglund, P Lindgren, B Jonsson, L Stawiarz, J Hillert

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.'. Together they form a unique fingerprint.

Medicine and Dentistry

Nursing and Health Professions

Psychology

Neuroscience